Research on a NEW Medication for Multiple Sclerosis

Video: https://youtu.be/rTRnbFpbG4Y

Millions live with multiple sclerosis. We’re two young researchers hoping to find a better future through a novel therapeutic peptide.

We’re Henry Hohm and Rasmus Schuster, two undergraduate medical students from Germany studying in the international English-language MD program at UMF “Victor Babeș” University of Medicine and Pharmacy Timișoara, Romania. Science brought us together. A shared passion for neuroscience—and a strong desire to help people with MS—turned us into research partners.

We’re now on the brink of something incredible: a once-in-a-lifetime opportunity to join a cutting-edge preclinical research team at the University of Southern California (USC), under the mentorship of award-winning professor Dr. Julio A. Camarero Palao. This lab will allow us to carry out the project we designed ourselves—something we cannot do in our home country due to missing infrastructure.

Our goal? To investigate a novel therapeutic peptide called BPC-157 in an experimental model of progressive multiple sclerosis (MS)—the most aggressive and least treatable form of the disease.

Multiple sclerosis affects over 2.8 million people globally. It’s a chronic, often debilitating neurological condition where the immune system attacks the protective sheath of nerve cells. For people with progressive MS, the outlook is especially devastating. No current treatments stop the progression. No known cure exists.

But there is hope.

BPC-157 is a small peptide derived from the body’s own protective proteins. It has shown promise in healing nerves, reducing inflammation, and protecting blood vessels in early studies—but it has never been tested in a validated model of progressive MS. That’s what we want to do.

Our study uses a preclinical model that mimics the slow, degenerative nature of progressive MS. With your support, we’ll test whether BPC-157 can reduce neurological damage and help preserve function. If successful, our work could lay the foundation for a completely new therapeutic avenue for MS—something safe, affordable, and accessible.

We’ve secured mentorship, lab access, and project approval at USC. Now, there’s just one barrier: funding.

We need to raise $31,000 to cover:

We’ve carefully budgeted every cent (see full breakdown in our description). We are pursuing scholarships and scientific foundations—but we can’t do it alone.

This is more than a student project. This is our commitment to those living with MS.

We’re not pharmaceutical companies. We’re not in this for profit. We’re two driven, idealistic medical students who believe in science, and in the people science should serve.

Every dollar brings us closer to uncovering a breakthrough.

If you believe in scientific curiosity, in giving young researchers a chance, and in a better future for people with MS—please consider donating.

From the bottom of our hearts: thank you.

—Henry & Rasmus